Skip to main content
Sister Publication Links
  • ESG: THE NEW IMPERATIVE
Subscribe
  • Sign Up Free
  • Login
  • Subscribe
  • News
    • Current News
    • COVID-19
    • Providers
    • Insurance
    • Government
    • Finance
    • Technology
    • Safety & Quality
    • Transformation
    • People
    • Regional News
    • Digital Edition (Web Version)
    • Patients
    • Operations
    • Care Delivery
    • Payment
    • Midwest
    • Northeast
    • South
    • West
  • Digital Health
  • Insights
    • ACA 10 Years After
    • Best Practices
    • Special Reports
    • Innovations
  • Opinion
    • Bold Moves
    • Breaking Bias
    • Commentaries
    • Letters
    • Vital Signs Blog
    • From the Editor
  • Events & Awards
    • Awards
    • Conferences
    • Galas
    • Virtual Briefings
    • Webinars
    • Nominate/Eligibility
    • 100 Most Influential People
    • 50 Most Influential Clinical Executives
    • Best Places to Work in Healthcare
    • Excellence in Governance
    • Health Care Hall of Fame
    • Healthcare Marketing Impact Awards
    • Top 25 Emerging Leaders
    • Top 25 Innovators
    • Diversity in Healthcare
      • - Luminaries
      • - Top 25 Diversity Leaders
      • - Leaders to Watch
    • Women in Healthcare
      • - Luminaries
      • - Top 25 Women Leaders
      • - Women to Watch
    • Digital Health Transformation Summit
    • Leadership Symposium
    • Social Determinants of Health Symposium
    • Women Leaders in Healthcare Conference
    • Best Places to Work Awards Gala
    • Health Care Hall of Fame Gala
    • Top 25 Diversity Leaders Gala
    • Top 25 Women Leaders Gala
    • - Hospital of the Future
    • - Value Based Care
    • - Supply Chain
    • - Hospital at Home
    • - Workplace of the Future
    • - Digital Health
    • - Future of Staffing
    • - Hospital of the Future (Fall)
  • Multimedia
    • Podcast - Beyond the Byline
    • Sponsored Podcast - Healthcare Insider
    • Video Series - The Check Up
    • Sponsored Video Series - One on One
  • Data Center
    • Data Center Home
    • Hospital Financials
    • Staffing & Compensation
    • Quality & Safety
    • Mergers & Acquisitions
    • Data Archive
    • Resource Guide: By the Numbers
    • Surveys
    • Data Points
  • MORE +
    • Contact Us
    • Advertise
    • Media Kit
    • Newsletters
    • Jobs
    • People on the Move
    • Reprints & Licensing
MENU
Breadcrumb
  1. Home
  2. Supply Chain
March 02, 2022 02:06 PM

Why Pfizer needs time to make its COVID pill

Associated Press
  • Tweet
  • Share
  • Share
  • Email
  • More
    Reprints Print
    pills and COVID
    MH Illustration/Getty Images

    Pfizer’s new COVID-19 treatment came with a catch when it debuted late last year: Supplies were limited, and it can take months to make the tablets.

    Company leaders say they are expanding production and expect big gains in the next several months. That could help if another wave of cases develops.

    What's the latest on supplies?

    The U.S. government distributes Paxlovid, the first pill authorized to treat the coronavirus. White House coronavirus response coordinator Jeff Zients said Wednesday that the government will have 1 million treatment courses available this month. He expects that to more than double in April.

    Pfizer Chief Global Supply Officer Mike McDermott says there is “an ample amount" of Paxlovid available for high-risk patients who need it.

    Physicians also have several other treatment options, including a less effective capsule treatment from Merck that U.S. regulators say should be considered only if other options aren’t available or appropriate.

    Not a Modern Healthcare subscriber? Sign up today.

    Dr. Raymund Razonable of the Mayo Clinic said Paxlovid supplies would have to increase if another surge materializes that's as big as the one caused recently by the omicron variant.

    Why does it take so long to make Paxlovid?

    The short answer: It's a complex drug that involves chemical reactions that need time to develop.

    Pfizer’s manufacturing experts compare Paxlovid to a complicated Lego model where key parts are made at different locations and then brought together and combined.

    The initial building blocks can take up to three months to make. Some chemical reactions need days to develop at a controlled temperature and pressure.

    “If you put it all in together very quickly, it can all go wrong,” said Charlotte Allerton, Pfizer’s head of medicine design.

    Those initial building blocks are shipped to another location that makes the main part of the drug, the active ingredient. Tack on another three months for that process.

    Then the ingredient heads to an additional location that turns it into tablets and packages the medicine. That can take six weeks. Add another week for quality checks and testing.

    Paxlovid production involves more than 20 different sites in over 10 countries.

    Is this time frame unusual?

    No. Pfizer executives say some drugs for other conditions take even longer.

    The company said it has already shaved average Paxlovid production time down to about seven months from close to nine.

    The drugmaker is adding more manufacturing and packaging sites. It will try to cut production time further, as long as it can do so without affecting quality.

    Merck says it takes about six months to make its treatment, molnupiravir. The company expects to reduce that to around five over time.

    Why use so many locations?

    Pfizer doesn’t have time to build a plant just to make Paxlovid.

    Merck also uses 17 plants across eight countries to make molnupiravir.

    “If you knew you were going to making this product for 10 years at a given scale, you’d probably build a plant just for it, but otherwise this is the way we typically do business,” said John McGrath, a Merck senior vice president.

    When did Pfizer start making Paxlovid?

    The company began preparations in June, about six months before the U.S. Food and Drug Administration authorized the medication. That also was before researchers finished late-stage studies on its effectiveness.

    Pfizer made its first commercial batch of the active ingredient at scale in September. The company then had to wait for FDA authorization before it could package and label.

    The drugmaker spent about $1 billion to get that head start, said Paul Duffy, a vice president with Pfizer Global Supply.

    Will supplies improve?

    Yes. McDermott said Pfizer expects to make 30 million patient packs by the middle of the year and 120 million by the end of 2022.

    Outside those totals, Pfizer is letting some generic drugmakers produce Paxlovid in a deal with the public health organization Medicines Patent Pool. That's expected to boost supply, especially for low-income countries.

    President Joe Biden announced Tuesday night that his administration will launch a “test to treat” plan that involves providing free antiviral pills at pharmacies to customers who test positive for the virus.

    When asked if Pfizer could handle additional demands from that program, a spokesman said the company was “confident in our supply capacity.” He added that the drugmaker remains on track to deliver 10 million treatment courses to the U.S. government by June.

    The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Department of Science Education. The AP is solely responsible for all content.

    Letter
    to the
    Editor

    Send us a letter

    Have an opinion about this story? Click here to submit a Letter to the Editor, and we may publish it in print.

    Recommended for You
    Flu vaccine
    Biden administration to release flu medicine from national stockpile
    COVID Test website
    Biden administration announces winter COVID plans, more free at-home tests
    Most Popular
    1
    More healthcare organizations at risk of credit default, Moody's says
    2
    Centene fills out senior executive team with new president, COO
    3
    SCAN, CareOregon plan to merge into the HealthRight Group
    4
    Blue Cross Blue Shield of Michigan unveils big push that lets physicians take on risk, reap rewards
    5
    Bright Health weighs reverse stock split as delisting looms
    Sponsored Content
    Daily Dose Newsletter: Sign up to receive a late afternoon weekday roundup of that day’s breaking news and developments in healthcare.
    Get Newsletters

    Sign up for enewsletters and alerts to receive breaking news and in-depth coverage of healthcare events and trends, as they happen, right to your inbox.

    Subscribe Today
    MH Magazine Cover

    MH magazine offers content that sheds light on healthcare leaders’ complex choices and touch points—from strategy, governance, leadership development and finance to operations, clinical care, and marketing.

    Subscribe
    Connect with Us
    • LinkedIn
    • Twitter
    • Facebook
    • RSS

    Our Mission

    Modern Healthcare empowers industry leaders to succeed by providing unbiased reporting of the news, insights, analysis and data.

    Contact Us

    (877) 812-1581

    Email us

     

    Resources
    • Contact Us
    • Advertise with Us
    • Ad Choices Ad Choices
    • Sitemap
    Editorial Dept
    • Submission Guidelines
    • Code of Ethics
    • Awards
    • About Us
    Legal
    • Terms and Conditions
    • Privacy Policy
    • Privacy Request
    Modern Healthcare
    Copyright © 1996-2023. Crain Communications, Inc. All Rights Reserved.
    • News
      • Current News
      • COVID-19
      • Providers
      • Insurance
      • Government
      • Finance
      • Technology
      • Safety & Quality
      • Transformation
        • Patients
        • Operations
        • Care Delivery
        • Payment
      • People
      • Regional News
        • Midwest
        • Northeast
        • South
        • West
      • Digital Edition (Web Version)
    • Digital Health
    • Insights
      • ACA 10 Years After
      • Best Practices
      • Special Reports
      • Innovations
    • Opinion
      • Bold Moves
      • Breaking Bias
      • Commentaries
      • Letters
      • Vital Signs Blog
      • From the Editor
    • Events & Awards
      • Awards
        • Nominate/Eligibility
        • 100 Most Influential People
        • 50 Most Influential Clinical Executives
        • Best Places to Work in Healthcare
        • Excellence in Governance
        • Health Care Hall of Fame
        • Healthcare Marketing Impact Awards
        • Top 25 Emerging Leaders
        • Top 25 Innovators
        • Diversity in Healthcare
          • - Luminaries
          • - Top 25 Diversity Leaders
          • - Leaders to Watch
        • Women in Healthcare
          • - Luminaries
          • - Top 25 Women Leaders
          • - Women to Watch
      • Conferences
        • Digital Health Transformation Summit
        • Leadership Symposium
        • Social Determinants of Health Symposium
        • Women Leaders in Healthcare Conference
      • Galas
        • Best Places to Work Awards Gala
        • Health Care Hall of Fame Gala
        • Top 25 Diversity Leaders Gala
        • Top 25 Women Leaders Gala
      • Virtual Briefings
        • - Hospital of the Future
        • - Value Based Care
        • - Supply Chain
        • - Hospital at Home
        • - Workplace of the Future
        • - Digital Health
        • - Future of Staffing
        • - Hospital of the Future (Fall)
      • Webinars
    • Multimedia
      • Podcast - Beyond the Byline
      • Sponsored Podcast - Healthcare Insider
      • Video Series - The Check Up
      • Sponsored Video Series - One on One
    • Data Center
      • Data Center Home
      • Hospital Financials
      • Staffing & Compensation
      • Quality & Safety
      • Mergers & Acquisitions
      • Data Archive
      • Resource Guide: By the Numbers
      • Surveys
      • Data Points
    • MORE +
      • Contact Us
      • Advertise
      • Media Kit
      • Newsletters
      • Jobs
      • People on the Move
      • Reprints & Licensing